RecruitingRecruiting
Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
NCT06657703 · HC Biopharma Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase Ia Single Center, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Doses of HC022 in Healthy Subjects
About this study
This is a first-in-human study of HC022 to assess safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) effects of single HC022 doses in healthy subjects.
Eligibility criteria
Inclusion Criteria:
1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and comply with study requirements;
2. Aged 18 to 55 years old, inclusive, male or female;
3. 3.A body weigh ≥ 50 kg for male , and a body weigh ≥ 45 kg for female, and must have a body mass index between 19 and 28 kilogram per square meter (kg/m2);
4. Be in good health as based on medical history, physical examination, vital signs, laboratory tests, chest radiographs, abdominal ultrasound and 12-lead ECG;
5. All women of childbearing potential and all men must practice highly effective contraception during the study and for 6 months (for female) or 3 months (for male) after their dose of study treatment;
Exclusion Criteria:
1. Have participated in other clinical trials within 3 months, or within the 5 half lives of the investigational drug prior to screening, whichever is longer;
2. History of or positive test results at screening for the following: for human immunodeficiency virus (HIV), hepatitis C virus antibody (HCV Ab), hepatitis B virus (defined as positive for HBsAg or HBcAb or HBeAg);
3. History of or current diagnosis of active tuberculosis (TB), or untreated latent TB infection (LTBI) at screening;
4. History of severe herpes infection or zoster viral infection;
5. Serious infection, serious injuries, or major surgical procedures within 6 months prior to Screening;
6. History of alcohol or substance abuse, a positive urine drug or alcohol test at Day -1;
7. History of severe allergic or anaphylactic reactions or history of allergic reactions likely to be exacerbated by any component of the study drug;
8. Any disease or conditons that are not suitable for participation in this study as determined by the Investigator;
Study design
Enrollment target: 38 participants
Allocation: randomized
Masking: double
Age groups: adult
Timeline
Starts: 2024-11-25
Estimated completion: 2026-01-08
Last updated: 2025-04-17
Interventions
Drug: HC022Drug: Placebo
Primary outcomes
- • Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (Up to 20 weeks)
Sponsor
HC Biopharma Inc. · industry
Contacts & investigators
ContactLangxi Zhang, PhD · contact · langxi.zhang@btyy.com · 8602150433368
ContactThe Clinical Pharmacology Research Center of PUMCH · contact
All locations (3)
Peking Union Medical College HospitalNot Yet Recruiting
Beijing, China
Peking Union Medical College HospitalRecruiting
Beijing, China
The Clinical Pharmacology Research Center of PUMCHRecruiting
Beijing, China